Brief: Cosmo Pharmaceuticals H1 EPS EUR 4.705
24/07/2024 06:46
Jul 24 (Reuters) - Cosmo Pharmaceuticals H1 net income EUR 76.058 million. * H1 operating expenses EUR -26.133 million * H1 EPS EUR 4.705 * H1 pretax profit EUR 88.748 million * H1 gross profit EUR 113.087 million * H1 operating income EUR 86.954 million * H1 revenue EUR 136.237 million * H1 EBITDA EUR 94.2 million
Recent news on Cosmo NV
See all newsFocus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
Ireland's Cosmo recurring revenue rises on winlevi growth, reaffirms FY guidance
Brief: Cosmo Pharmaceuticals H1 EPS EUR -0.279
Cosmo Pharma's male hair loss treatment shows sustained hair growth in year‑long study
Europe Research Roundup: Airbus ,Bechtle, Salzgitter